ArticleJournal of tissue engineering and regenerative medicine2018
Tissue engineered nigrostriatal pathway for treatment of Parkinson's disease.
Article in Journal of tissue engineering and regenerative medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 63 citations in OpenAlex.
- Phytoconstituents as Potential Therapeutics against Enzymatic Targets for Neurodegenerative Diseases.Current protein & peptide science · 2026Review
- Biomaterials for CNS disorders: a review of development from traditional methods to AI-assisted optimization.Journal of materials science. Materials in medicine · 2025Review
- Gradients of Nigrostriatal Iron Deposition in Healthy Aging and Synucleinopathies.CNS neuroscience & therapeutics · 2025Article
- Bio-inspired electronics: Soft, biohybrid, and "living" neural interfaces.Nature communications · 2025Review
- Dopaminergic Axon Tracts Within a Hyaluronic Acid Hydrogel Encasement to Restore the Nigrostriatal Pathway.Advanced healthcare materials · 2025Article
- Human Nasal Inferior Turbinate-Derived Neural Stem Cells Improve the Niche of Substantia Nigra Par Compacta in a Parkinson's Disease Model by Modulating Hippo Signaling.Tissue engineering and regenerative medicine · 2024Article
- Biomaterials and Cell Therapy Combination in Central Nervous System Treatments.ACS applied bio materials · 2024Review
- Generation of contractile forces by three-dimensional bundled axonal tracts in micro-tissue engineered neural networks.Frontiers in molecular neuroscience · 2024Article
- Cell Replacement Therapy for Brain Repair: Recent Progress and Remaining Challenges for Treating Parkinson's Disease and Cortical Injury.Brain sciences · 2023Review
- Hydrogen Sulphide-Based Therapeutics for Neurological Conditions: Perspectives and Challenges.Neurochemical research · 2023Review
- Emergent structural and functional properties of hippocampal multi-cellular aggregates.Frontiers in neuroscience · 2023Article
- Bedside to bench: the outlook for psychedelic research.Frontiers in pharmacology · 2023Review
- Engineered neuronal microtissue provides exogenous axons for delayed nerve fusion and rapid neuromuscular recovery in rats.Bioactive materials · 2022Article
- Stem Cell-based and Advanced Therapeutic Modalities for Parkinson's Disease: A Risk-effectiveness Patient-centered Analysis.Current neuropharmacology · 2022Review
- Axonal Tract Reconstruction Using a Tissue-Engineered Nigrostriatal Pathway in a Rat Model of Parkinson's Disease.International journal of molecular sciences · 2022Article
- Nanomedicine in the Face of Parkinson's Disease: From Drug Delivery Systems to Nanozymes.Cells · 2022Review
- Biomaterial and tissue-engineering strategies for the treatment of brain neurodegeneration.Neural regeneration research · 2022Review
- Multimodular Bio-Inspired Organized Structures Guiding Long-Distance Axonal Regeneration.Biomedicines · 2022Article
- Multiparametric Material Functionality of Microtissue-Based In Vitro Models as Alternatives to Animal Testing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Unique Astrocyte Cytoskeletal and Nuclear Morphology in a Three-Dimensional Tissue-Engineered Rostral Migratory Stream.Neuroglia (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
The classic motor deficits of Parkinson's disease are caused by degeneration of dopaminergic neurons in the substantia nigra pars compacta, resulting in the loss of their long-distance axonal projections that modulate the striatum. Current treatments only minimize the symptoms of this disconnection as there is no approach capable of replacing the nigrostriatal pathway. We are applying microtissue engineering techniques to create living, implantable constructs that mimic the architecture and function of the nigrostriatal pathway. These constructs consist of dopaminergic neurons with long axonal tracts encased within hydrogel microcolumns. Microcolumns were seeded with dopaminergic neuronal aggregates, while lumen extracellular matrix, growth factors, and end targets were varied to optimize cytoarchitecture. We found a 10-fold increase in axonal outgrowth from aggregates versus dissociated neurons, resulting in remarkable axonal lengths of over 6 mm by 14 days and 9 mm by 28 days in vitro. Axonal extension was also dependent upon lumen extracellular matrix, but did not depend on growth factor enrichment or neuronal end target presence. Evoked dopamine release was measured via fast scan cyclic voltammetry and synapse formation with striatal neurons was observed in vitro. Constructs were microinjected to span the nigrostriatal pathway in rats, revealing survival of implanted neurons while maintaining their axonal projections within the microcolumn. Lastly, these constructs were generated with dopaminergic neurons differentiated from human embryonic stem cells. This strategy may improve Parkinson's disease treatment by simultaneously replacing lost dopaminergic neurons in the substantia nigra and reconstructing their long-projecting axonal tracts to the striatum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.